Dr. Derrick R. Ward, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- Southern Illinois University School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 415
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Southern Illinois University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
MO license 2003009413
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Midwest Physician Group LLC (24 clinicians)
- Kansas City Allergy and Asthma Associates P A (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 415
- Services billed
- 16,134
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,578 | 45 |
| Professional service for preparation and provision of 1 or more antigens | 2,208 | 66 |
| Professional service for multiple injections of allergen | 761 | 57 |
| Test for allergy using allergenic extract injected into skin | 483 | 32 |
| Test to measure rate of airflow | 229 | 128 |
| Established patient office or other outpatient visit, 20-29 minutes | 224 | 172 |
| Professional service for single injection of allergen | 176 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 156 | 101 |
| Administration and interpretation of patient-focused health risk assessment | 128 | 90 |
| New patient office or other outpatient visit, 30-44 minutes | 74 | 74 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Overland PArk, KS | 192 |
| Azelastine Hcl Other prescribers in Overland PArk, KS | 105 |
| Fluticasone Propionate Other prescribers in Overland PArk, KS | 104 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Overland PArk, KS | 86 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Overland PArk, KS | 85 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Overland PArk, KS | 79 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Overland PArk, KS | 56 |
| Omeprazole Other prescribers in Overland PArk, KS | 37 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Overland PArk, KS | 34 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Overland PArk, KS | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 99 payments worth $1,648 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $246 |
|---|---|
| GlaxoSmithKline, LLC. | $223 |
| Genzyme Corporation | $212 |
| Regeneron Healthcare Solutions, Inc. | $204 |
| Amgen Inc. | $95.07 |
| Grifols USA, LLC | $89.62 |
| Takeda Pharmaceuticals U.S.A., Inc. | $67.87 |
| Ars Pharmaceuticals Operations, Inc. | $56.92 |
| Food and Beverage | $1,600 |
|---|---|
| Consulting Fee | $47.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Adma Biomanufacturing LLC Jul 7, 2025 | Consulting Fee | $26.04 |
| Adma Biomanufacturing LLC Feb 11, 2025 | Consulting Fee | $21.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $1,070,214 in research payments for these studies, mostly to the institutions running them.
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Sanofi Pasteur Inc. · Active, not recruiting · NCT06686654 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morb…
AstraZeneca Pharmaceuticals LP - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT05330975 - A Cross Sectional Observational Primary Data Collection Study to Assess the Validity of the US Pediatric Asthma Impairment and Risk Questionnaire AIRQ as a Tool that Identifies Pediatric Patients with Current Uncontro…
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
ModernaTX, Inc. · Completed · NCT06097299 - Registry of Asthma Patients Initiating DUPIXENT®
Regeneron Pharmaceuticals, Inc. · Completed · NCT04287621
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.